Efficacy of the Free Radical Scavenger, Edaravone, for Motor Palsy of Acute Lacunar Infarction

Ohta, Yasuyuki; Takamatsu, Kazuhiro; Fukushima, Tomoko; Ikegami, Satomi; Takeda, Ikuko; Ota, Tsuguhito; Goto, Katsuya; Abe, Kōji

doi:10.2169/internalmedicine.48.1871

Cited by 26 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical studies on patients with acute lacunar infarction have also shown efficacy of edaravone in improving the functional outcome; In one recent study on 124 participants, combination of edaravone and conventional therapy was superior to conventional therapy and significantly improved the outcome (especially motor palsy) of patients [63]. A previous study on 70 patients of acute lacunar infarction had similarly shown that administration of this drug improves the functional outcome in these patients [64].…”

Section: Reactive Oxygen Speciesmentioning

confidence: 95%

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Miotto¹,

Striebel²,

Cho

et al. 2013

Drug and Alcohol Dependence

121

View full text Add to dashboard Cite

Abstract:Reactive oxygen species (ROS) are widely believed to cause or aggravate several human pathologies such as neurodegenerative diseases, cancer, stroke and many other ailments. Antioxidants are assumed to counteract the harmful effects of ROS and therefore prevent or treat oxidative stress-related diseases. In this report, recent human studies exploring the efficiency of antioxidants in prevention and treatment of various diseases are reviewed. Few antioxidants including edaravone (for ischemic stroke in Japan), Nacetylcysteine (for acetaminophen toxicity), alfa-lipoic acid (for diabetic neuropathy) and some flavonoids (polyphenolic compounds present in dietary plants), such as micronized purified flavonoid fraction (diosmin and hesperidin) and oxerutins (for chronic venous insufficiency) as well as baicalein and catechins (for osteoarthritis) have found accepted clinical use. However, despite much enthusiasm in the 1980s and 1990s, many well-known agents such as antioxidant vitamins and also more recently developed compounds such as nitrones have not successfully passed the scrutiny of clinical trials for prevention and treatment of various diseases. This has given rise to a pessimistic view of antioxidant therapy, however, the evidence from human epidemiological studies about the beneficial effects of dietary antioxidants and preclinical in vitro and animal data are compelling. We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants. We here discuss possible reasons for the lack of success in some clinical trials and seek to provide some suggestions to be considered if antioxidant therapy is to succeed as an effective therapeutic strategy.

show abstract

Section: Reactive Oxygen Speciesmentioning

confidence: 95%

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Miotto¹,

Striebel²,

Cho

et al. 2013

Drug and Alcohol Dependence

121

View full text Add to dashboard Cite

show abstract

“…Edaravone is a free radical scavenger and neuroprotectant, which was approved in Japan in 2001 as an adjunct treatment of ischemic stroke within 24 h of symptom onset [11][12][13][14]. In the present study, the edaravone group, even within 3-4.5 h following symptom onset, might suggest higher rates of recanalization than the non-edaravone group.…”

Section: Discussionmentioning

confidence: 61%

“…Edaravone is a free radical scavenger used for neurovascular protection in cerebral infarction and was approved for adjunct therapy in Japan in 2001 [11][12][13][14]. In addition to acute ischemic stroke patients in Japan, most acute ischemic stroke patients in China [15] and India [16] now receive edaravone in combination with tPA treatment.…”

Section: Introductionmentioning

confidence: 99%

Thrombolysis with Low-Dose Tissue Plasminogen Activator 3–4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan

Morihara

Kono

Sato

et al. 2016

Transl. Stroke Res.

Self Cite

View full text Add to dashboard Cite

Clinical data from Japan on the safety and real-world outcomes of alteplase (tPA) thrombolysis in the extended therapeutic window are lacking. The aim of this study was to assess the safety and real-world outcomes of tPA administered within 3-4.5 h of stroke onset. The study comprised consecutive acute ischemic stroke patients (n = 177) admitted across five hospitals between September 2012 and August 2014. Patients received intravenous tPA within <3 or 3-4.5 h of stroke onset. Endovascular therapy was used for tPA-refractory patients. In the 3-4.5 h subgroup (31.6 % of patients), tPA was started 85 min later than the <3 h group (220 vs. 135 min, respectively). However, outcome measures were not significantly different between the <3 and 3-4.5 h subgroups for recanalization rate (67.8 vs. 57.1 %), symptomatic intracerebral hemorrhage (2.5 vs. 3.6 %), modified Rankin Scale score of 0-1 at 3 months (36.0 vs. 23.4 %), and mortality (6.9 vs. 8.3 %). We present data from 2005 to 2012 using a therapeutic window <3 h showing comparable results. tPA following endovascular therapy with recanalization might be superior to tPA only with recanalization (81.0 vs. 59.1 %). Compared with administration within 3 h of ischemic stroke onset, tPA administration within 3-4.5 h of ischemic stroke onset in real-world stroke emergency settings at multiple sites in Japan is as safe and has the same outcomes.

show abstract

“…Edaravone does not affect blood coagulation, platelet aggregation, fibrinolysis, or bleeding time [11,12]; therefore, there is no additional risk of bleeding. It has been shown to clinically improve neurological deficits after cerebral infarction in adult patients [9,13]. Shinohara Y. et al verified in a multicenter randomized parallel-group open-label trial that edaravone was as effective as ozagrel for the treatment of acute non-cardioembolic ischemic stroke [14].…”

Section: Discussionmentioning

confidence: 99%

Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone

et al. 2015

View full text Add to dashboard Cite

show abstract

Efficacy of the Free Radical Scavenger, Edaravone, for Motor Palsy of Acute Lacunar Infarction

Cited by 26 publications

References 15 publications

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Thrombolysis with Low-Dose Tissue Plasminogen Activator 3–4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan

Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone

Contact Info

Product

Resources

About